FDA green and red lights: April 2024
A tumour-agnostic label for Enhertu leads April’s US oncology approvals.
A tumour-agnostic label for Enhertu leads April’s US oncology approvals.
Abstract titles reveal some of ASCO’s key datasets.
An analysis of OncologyPipeline shows that $144bn has been pledged for ADCs since the start of 2022.
A roundup of the first quarter's key oncology drug approvals and rejections.
The takeover of AnHeart centres on advancing the latter’s targeted lung cancer project taletrectinib.
The Echelon-3 study seemed doomed, but it just read out positively for overall survival.
Another disappointment raises fresh doubts about CytomX’s extensively partnered masked therapeutics.